Literature DB >> 18649128

A dual-purpose protein ligand for effective therapy and sensitive diagnosis of anthrax.

Momchilo Vuyisich1, S Gnanakaran, Julie A Lovchik, C Rick Lyons, Goutam Gupta.   

Abstract

This article reports the design of a bivalent protein ligand with dual use in therapy and diagnosis of anthrax caused by Bacillus anthracis. The ligand specifically binds to PA and thereby blocks the intracellular delivery of LF and EF toxins that, respectively, cause cell lysis and edema. The ligand is a chimeric scaffold with two PA-binding domains (called VWA) linked to an IgG-Fc frame. Molecular modeling and binding measurements reveal that the VWA-Fc dimer binds to PA with high affinity (K(D)=0.2 nM). An in vitro bio-luminescence assay shows that VWA-Fc (at nanomolar concentration) protects mouse macrophages from lysis by PA/LF. In vivo studies demonstrate that VWA-Fc at low doses (approximately 50 microg/animal) are able to rescue animals from lethal doses of PA/LF and B. anthracis spores. Finally, VWA-Fc is utilized as the capture molecule in the sensitive (down to 30 picomolar) detection of PA using surface plasmon resonance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18649128     DOI: 10.1007/s10930-008-9137-0

Source DB:  PubMed          Journal:  Protein J        ISSN: 1572-3887            Impact factor:   2.371


  38 in total

1.  Structure-based design of a bispecific receptor mimic that inhibits T cell responses to a superantigen.

Authors:  N M Lehnert; D L Allen; B L Allen; P Catasti; P R Shiflett; M Chen; B E Lehnert; G Gupta
Journal:  Biochemistry       Date:  2001-04-10       Impact factor: 3.162

2.  Design of chimeric receptor mimics with different TcRVbeta isoforms. Type-specific inhibition of superantigen pathogenesis.

Authors:  Elizabeth Hong-Geller; Margit Möllhoff; Patrick R Shiflett; Goutam Gupta
Journal:  J Biol Chem       Date:  2003-11-06       Impact factor: 5.157

3.  Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for receptor in pH-dependent pore formation.

Authors:  D Borden Lacy; Darran J Wigelsworth; Roman A Melnyk; Stephen C Harrison; R John Collier
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

4.  Human alpha-defensins neutralize anthrax lethal toxin and protect against its fatal consequences.

Authors:  Chun Kim; Nadesan Gajendran; Hans-Willi Mittrücker; Matthias Weiwad; Young-Hwa Song; Robert Hurwitz; Matthias Wilmanns; Gunter Fischer; Stefan H E Kaufmann
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-16       Impact factor: 11.205

5.  Crystal structure of a complex between anthrax toxin and its host cell receptor.

Authors:  Eugenio Santelli; Laurie A Bankston; Stephen H Leppla; Robert C Liddington
Journal:  Nature       Date:  2004-07-04       Impact factor: 49.962

6.  Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody.

Authors:  M J Rosovitz; Peter Schuck; Mini Varughese; Arun P Chopra; Varsha Mehra; Yogendra Singh; Lisa M McGinnis; Stephen H Leppla
Journal:  J Biol Chem       Date:  2003-05-27       Impact factor: 5.157

7.  A homogeneous assay to measure live and dead cells in the same sample by detecting different protease markers.

Authors:  Andrew L Niles; Richard A Moravec; P Eric Hesselberth; Michael A Scurria; William J Daily; Terry L Riss
Journal:  Anal Biochem       Date:  2007-04-12       Impact factor: 3.365

8.  Macromolecular recognition in the Protein Data Bank.

Authors:  Joël Janin; Francis Rodier; Pinak Chakrabarti; Ranjit P Bahadur
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2006-12-13

9.  Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen.

Authors:  Zhaochun Chen; Mahtab Moayeri; Yi-Hua Zhou; Stephen Leppla; Suzanne Emerson; Andrew Sebrell; Fujuan Yu; Juraj Svitel; Peter Schuck; Marisa St Claire; Robert Purcell
Journal:  J Infect Dis       Date:  2006-02-02       Impact factor: 5.226

10.  Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed.

Authors:  Ritsuko Sawada-Hirai; Ivy Jiang; Fei Wang; Shu Man Sun; Rebecca Nedellec; Paul Ruther; Alejandro Alvarez; Diane Millis; Phillip R Morrow; Angray S Kang
Journal:  J Immune Based Ther Vaccines       Date:  2004-05-12
View more
  9 in total

1.  Binding and cell intoxication studies of anthrax lethal toxin.

Authors:  Momchilo Vuyisich; Claire K Sanders; Steven W Graves
Journal:  Mol Biol Rep       Date:  2012-01-05       Impact factor: 2.316

Review 2.  An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis.

Authors:  Lernik Ohanjanian; Kenneth E Remy; Yan Li; Xizhong Cui; Peter Q Eichacker
Journal:  Expert Opin Investig Drugs       Date:  2015-04-28       Impact factor: 6.206

3.  Recombinant anthrax toxin receptor-Fc fusion proteins produced in plants protect rabbits against inhalational anthrax.

Authors:  Keith L Wycoff; Archana Belle; Dorothée Deppe; Leah Schaefer; James M Maclean; Simone Haase; Anke K Trilling; Shihui Liu; Stephen H Leppla; Isin N Geren; Jennifer Pawlik; Johnny W Peterson
Journal:  Antimicrob Agents Chemother       Date:  2010-10-18       Impact factor: 5.191

Review 4.  Receptors of anthrax toxin and cell entry.

Authors:  Gisou van der Goot; John A T Young
Journal:  Mol Aspects Med       Date:  2009-09-02

5.  Delayed toxicity associated with soluble anthrax toxin receptor decoy-Ig fusion protein treatment.

Authors:  Diane Thomas; John Naughton; Christopher Cote; Susan Welkos; Marianne Manchester; John A T Young
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

6.  A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein.

Authors:  Michael S Rogers; Lorna M Cryan; Kaiane A Habeshian; Lauren Bazinet; Thomas P Caldwell; P Christine Ackroyd; Kenneth A Christensen
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

7.  Improving the anti-toxin abilities of the CMG2-Fc fusion protein with the aid of computational design.

Authors:  Yongyi Xi; Xiaojie Wu; Lihua Gao; Yong Shao; Hui Peng; Hongxing Chen; Huipeng Chen; Xianwen Hu; Junjie Yue
Journal:  PLoS One       Date:  2014-08-07       Impact factor: 3.240

8.  Recombinant HSA-CMG2 Is a Promising Anthrax Toxin Inhibitor.

Authors:  Liangliang Li; Qiang Guo; Ju Liu; Jun Zhang; Ying Yin; Dayong Dong; Ling Fu; Junjie Xu; Wei Chen
Journal:  Toxins (Basel)       Date:  2016-01-20       Impact factor: 4.546

Review 9.  Roles of Anthrax Toxin Receptor 2 in Anthrax Toxin Membrane Insertion and Pore Formation.

Authors:  Jianjun Sun; Pedro Jacquez
Journal:  Toxins (Basel)       Date:  2016-01-22       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.